Associations of neutrophil to albumin ratio with acute adverse events and survival in patients with pathological stage Ⅱ/Ⅲ rectal cancer receiving adjuvant chemoradiotherapy
10.3760/cma.j.issn.0254-5098.2019.09.005
- VernacularTitle: 中性粒细胞与白蛋白比值预测病理Ⅱ/Ⅲ期直肠癌术后辅助放化疗急性不良反应和生存
- Author:
Yanru FENG
1
;
Luying LIU
;
Yuan ZHU
Author Information
1. Department of Radiation Oncology, Institute of Cancer Research and Basic Medical Sciences of Chinese Academy of Sciences, Cancer Hospital of University of Chinese Academy of Sciences, Zhejiang Cancer Hospital, Hangzhou 310022, China
- Publication Type:Journal Article
- Keywords:
Rectal cancer;
Neutrophil to albumin ratio;
Chemoradiotherapy;
Acute adverse event;
Survival
- From:
Chinese Journal of Radiological Medicine and Protection
2019;39(9):663-667
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To evaluate whether any association exists between peripheral blood cell-based inflammatory biomarkers obtained before adjuvant chemoradiotherapy and adverse events (AEs) and survival of patients with pathological stage Ⅱ/Ⅲ rectal cancer treated by adjuvant chemoradiotherapy.
Methods:A total of 109 rectal cancer patients were included. The prognostic abilities of neutrophil to lymphocyte ratio (NLR), platelet to lymphocyte ratio (PLR), lymphocyte to monocyte ratio (LMR) and neutrophil to albumin ratio (NAR) for overall survival (OS) were calculated by the receiver operating characteristic (ROC) curves.
Results:NAR was associated with the occurrence of grade ≥2 leukopenia (OR=4.442, 95% CI: 1.216-16.221, P<0.05). The 5-year OS rates of patients with NAR ≥ 0.055 and patients with NAR<0.055 were 68.2% and 83.9%, respectively (P>0.05). The 5-year disease-free survival (DFS) rates of patients with NAR ≥ 0.055 and patients with NAR<0.055 were 59.1% and 76.8%, respectively (χ2=3.887, P<0.05). Multivariate analysis by Cox proportional-hazards model showed that NAR was significantly associated with OS (HR=3.035, 95% CI: 1.021-9.019, P<0.05).
Conclusions:These results suggest that NAR obtained before adjuvant chemoradiotherapy might serve as an independent biomarker for predicting AEs and prognosis in rectal cancer treated with adjuvant chemoradiotherapy.
